Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial
European Journal of Cancer · 2026-10 · 247 · 117045
DOI: 10.1016/j.ejca.2026.117045 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-10. Verfasst von Tshilidzi M Klingler und 16 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum Esslingen, Esslingen, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Quality of Life, Camptothecin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Klinikum Esslingen, Esslingen, Germany.
- SLK Kliniken Klinikum am Gesundbrunnen, Heilbronn, Germany.
- Universitätsklinik Marburg, Marburg, Germany.
- Universitätsklinikum Ulm, Ulm, Germany.
- Leopoldina Krankenhaus, Schweinfurt, Germany.
- Charité Comprehensive Cancer Center, Charité Universitätsmedizin Berlin, Berlin, Germany.
Zitieren
APA
Klingler, T. M., Martens, U. M., Riera-Knorrenschild, J., Wessendorf, S., Ettrich, T., Kanzler, S., Lugani, S., Rohleder, E., Stahler, A., Hasenburg, A. A., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Geissler, M., Modest, D. P., & Werner, J. (2026). Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial. European Journal of Cancer, 247, 117045. https://doi.org/10.1016/j.ejca.2026.117045
Vancouver
Klingler TM, Martens UM, Riera-Knorrenschild J, Wessendorf S, Ettrich T, Kanzler S, et al. Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial. European Journal of Cancer. 2026;247:117045. doi:10.1016/j.ejca.2026.117045
BibTeX
@article{Klingler2026,
author = {Klingler, Tshilidzi M and Martens, Uwe M and Riera-Knorrenschild, Jorge and Wessendorf, Swen and Ettrich, Thomas and Kanzler, Stephan and Lugani, Sophie and Rohleder, Elena and Stahler, Arndt and Hasenburg, Alena A and Held, Swantje and Buechner-Steudel, Petra and Atzpodien, Jens and Heinemann, Volker and Geissler, Michael and Modest, Dominik P and Werner, Johannes},
title = {Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial},
journal = {European Journal of Cancer},
year = {2026},
volume = {247},
pages = {117045},
doi = {10.1016/j.ejca.2026.117045}
}
EUVIMED